Stockscreener 앱 받기
37.58
1.54%
0.57
시간 외 거래:
37.58
전일 마감가:
$37.01
열려 있는:
$37.14
하루 거래량:
2.81M
Relative Volume:
0.74
시가총액:
$15.84B
수익:
$2.26B
순이익/손실:
$1.09B
주가수익비율:
16.04
EPS:
2.3431
순현금흐름:
$2.70B
1주 성능:
+1.27%
1개월 성능:
+5.83%
6개월 성능:
+18.44%
1년 성능:
+43.71%
1일 변동 폭
$36.93
$37.97
1주일 범위
$36.27
$38.00
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.58 | 15.64B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stock Position Lifted by Koss Olinger Consulting LLC - MarketBeat
Cary Street Partners Financial LLC Invests $610,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma: Keep Delivering, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighWhat's Next? - MarketBeat
Royalty Pharma’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream - insights.citeline.com
UBS Adjusts Price Target on Royalty Pharma to $37 From $36, Maintains Neutral Rating - MarketScreener
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
Royalty Pharma Reports Strong Q2 2025 Results - TipRanks
Royalty Pharma (RPRX) Q2 Receipts Up 20% - AOL.com
Royalty Pharma Plc Q2 Income Retreats - Nasdaq
Royalty Pharma Raises 2025 Portfolio Receipts Guidance to $3.05B-$3.15B, Achieving 20% Growth in Top Line - AInvest
Royalty Management Holding Corporation shares rise 5.65% intraday after Royalty Pharma plc reports Q2 2025 results. - AInvest
Royalty Pharma stock price target raised to $48 from $42 at BofA Securities - Investing.com UK
Royalty Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma (RPRX) PT Raised to $48 at BofA Securities - StreetInsider
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Royalty Pharma earnings missed by $0.99, revenue fell short of estimates - Investing.com Nigeria
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth By Investing.com - Investing.com Nigeria
Royalty Pharma plc SEC 10-Q Report - TradingView
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth - Investing.com
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings - Yahoo Finance
Transcript : Royalty Pharma plc, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Royalty Pharma reports second quarter 2025 results - MarketScreener
Royalty Pharma Q2 2025 slides: Double-digit growth and raised guidance - Investing.com Nigeria
Royalty Pharma Q2 Net Income Falls, Revenue Rises - MarketScreener
Royalty Pharma Reports Second Quarter 2025 Results - TradingView
Earnings Flash (RPRX) Royalty Pharma plc Reports Q2 Revenue $579.0M - MarketScreener
53,119 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by XTX Topco Ltd - MarketBeat
Mackenzie Financial Corp Purchases 205,356 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
HB Wealth Management LLC Invests $392,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 37.91 USD - Investing.com
Royalty Pharma stock hits 52-week high at 37.91 USD By Investing.com - Investing.com Canada
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Royalty Pharma (RPRX) Expected to Announce Earnings on Wednesday - MarketBeat
Torray Investment Partners LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What are Royalty Pharma plc company’s key revenue driversIdentify safe investments with exceptional yields - Jammu Links News
What drives Royalty Pharma plc stock priceGet timely alerts on top market movers - Jammu Links News
What analysts say about Royalty Pharma plc stockDiscover breakthrough stocks with expert help - Jammu Links News
Should I hold or sell Royalty Pharma plc stock in 2025Build wealth faster with consistent investment plans - Jammu Links News
TD Asset Management Inc Boosts Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What markets is GCLWW expanding into Is Royalty Pharma plc stock a good long term investment option - Jammu Links News
What are analysts’ price targets for Royalty Pharma plc in the next 12 monthsUnmatched market gains - Jammu Links News
When is Royalty Pharma plc stock expected to show significant growthBuild a winning investment strategy today - Jammu Links News
What makes Royalty Pharma plc stock price move sharplyAchieve consistent high returns with low risk - Jammu Links News
Is Royalty Pharma plc stock overvalued or undervaluedGet timely alerts on top market movers - Jammu Links News
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):